Lactoferrin for Immune Function

Verdict: Weak, population-dependent evidence; not a proven immune booster

Lactoferrin shows a modest signal for fewer respiratory infections in infants and children, but it does not work for adult immunity and failed to prevent infection in the largest, best-designed neonatal trial. No health authority endorses it for immune function, so any "boosts immunity" claim is overstated.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade lands at Weak because the evidence is split by age and contradicts itself at the highest level of rigor. Pooled meta-analyses suggest fewer respiratory tract infections in children (2021 meta-analysis OR 0.57, PMID 34620326; 2022 review OR 0.78 in infants/children, PMID 35481594), and a small preschool RCT reported roughly half as many episodes (PMID 38397361, n=50). But that trial is tiny and single-center, and the same 2022 review found no effect in adults (OR 1.00).

Most importantly, the largest and best-powered trial is null. ELFIN (PMID 30635141, n=2203, UK NIHR-funded) found no reduction in late-onset sepsis in very preterm infants (adjusted RR 0.95, 95% CI 0.86-1.04, p=0.233), directly overturning the earlier, smaller, industry-supported Manzoni/LISA trial that had reported a large benefit (PMID 40507041, n=472, RR 0.34). A positive small-trial signal that vanishes at scale is a classic small-study effect.

No major authority backs lactoferrin for immunity. FDA and EFSA accept it only as a safe food ingredient (GRAS and novel food), not as an immune therapy with an approved health claim, and the WHO, NHS, NIH ODS, Mayo Clinic, Cleveland Clinic and Harvard Health offer no endorsement. That institutional silence, the null adult and hard-endpoint data, and heterogeneous doses justify a cautious Weak verdict rather than a stronger one.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
79%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial (ELFIN)
PMID: 30635141 2019 隨機對照試驗 n = 2,203
Finding: ELFIN was NULL: 316/1093 (29%) in lactoferrin group vs 334/1089 (31%) in placebo developed late-onset sepsis; adjusted RR 0.95 (95% CI 0.86 to 1.04, p=0.233). No reduction in morbidity or mortality. Authors concluded the data do not support routine use to prevent late-onset infection in very preterm infants.
🟢 High quality Mixed funding Effect size: Adjusted RR 0.95 (95% CI 0.86-1.04), NS
View on PubMed
Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials
PMID: 34620326 2021 統合分析 n = 1,194
Finding: Pooled OR 0.57 (95% CI 0.44-0.74) — approximately 43% lower odds of developing RTI in lactoferrin-supplemented group vs control. Lactoferrin also reduced symptom frequency and duration.
Effect size: OR 0.57 (95% CI 0.44-0.74)
View on PubMed
Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections in Humans: A Systematic Review and Meta-analysis
PMID: 35481594 2022 統合分析
Finding: 25 studies (20 adults). RTI incidence reduced in infants/children (OR 0.78) but NOT in adults (OR 1.00). IL-6 reduced by mean difference -24.9 pg/mL in adults. 61% of adult studies showed decreased systemic inflammatory biomarkers; 75% showed improved immune function markers.
Effect size: RTI OR 0.78 (children); OR 1.00 (adults, NS); IL-6 MD -24.9 pg/mL
View on PubMed
Lactoferrin in the Prevention of Recurrent Respiratory Infections in Preschool Children: A Prospective Randomized Study
PMID: 38397361 2024 隨機對照試驗 n = 50
Finding: Lactoferrin group had 50% reduction in median respiratory infection episodes (1 vs 2, p=0.02); 80% lower odds of upper RTI; corticosteroid use 32% vs 60% (p=0.047). Symptom duration and school absence also reduced.
🟠 Limited quality Effect size: OR 0.20 for URTI; median episodes 1 vs 2
View on PubMed
Bovine Lactoferrin Supplementation for Prevention of Late-Onset Sepsis in Very Low-Birth-Weight Neonates: A Randomized Trial (LISA / Manzoni et al., JAMA)
PMID: 40507041 2025 隨機對照試驗 n = 472
Finding: Significant reduction: late-onset sepsis incidence 5.9% (BLF) and 4.6% (BLF+LGG) vs 17.3% (placebo). RR 0.34 (95% CI 0.17-0.70) for BLF alone vs placebo. Effect did not depend on LGG co-administration.
Mixed funding Effect size: RR 0.34 (95% CI 0.17-0.70) for BLF vs placebo
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Supportive
L4d TW TFDA / 衛福部
Supportive
第(八)類 營養添加劑 編號08112 乳鐵蛋白 — 自中華民國一百十二年一月一日施行 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-immune-function-INT-lactoferrin-001 繁體中文版 →